RxGrab Research // Stats Page

85 Prescription Drug Pricing Statistics 2026 (Brand vs Generic, Patent Cliff, Insurance Coverage)

Last updated: · Editorial Review Pending

The open dataset behind The RxGrab Real-Price Standard, our independent conflict-free drug-price standard.

Cite this dataset: Couey, V.W. (2026). 85 Prescription Drug Pricing Statistics 2026. RxGrab. CC BY 4.0. https://rxgrab.com/prescription-drug-statistics-2026/

A curated, hyperlink-sourced reference for US prescription drug pricing in 2026. Every stat links to its primary source. We omit any number we cannot verify.

Medical disclaimer: This page is a pricing reference, not medical advice. Drug substitution, dosing, and adherence decisions belong to a licensed clinician or pharmacist. Some patients have legitimate clinical reasons to remain on brand formulations.
US prescription drug spending by year US prescription drug spending (USD billions, net of rebates) $369B $487B 2018 2019 2020 2021 2022 2023 2024 $500B $420B $340B Source: IQVIA Use of Medicines, CMS NHE projections
US prescription drug net spending crossed $480 billion in 2024 per IQVIA Use of Medicines in the US 2024, against gross spending above $720 billion. The net-vs-gross gap is the rebate stack negotiated between manufacturers and PBMs.

Generics: Volume vs Spend

Share of prescriptions90%
Share of drug spending13.1%

Generics and biosimilars fill 90% of US prescriptions yet account for only 13.1% of prescription drug spending (AAM 2024).

Specialty: Spend vs Volume

Share of drug spending~55%
Share of prescriptions~2%

The mirror image: specialty drugs are ~2% of prescriptions but ~55% of spending (IQVIA 2024).

Cash-Price Floors

$5.32 metformin 500mg (Cost Plus)$4 Walmart genericsCostco: no published listCost Plus: cost + 15% + $5$3 trillion+ generic savings, decade to 2023

What competitive generics do to cash prices once the patent cliff clears.

US drug prices as a multiple of the OECD comparator average, RAND 2024 (2022 prices) US prices vs a 33-country OECD basket (RAND 2024, 2022 prices) OECD average = 1.0x 4.22x 2.78x 67% US brand-name US, all drugs US generic Source: RAND Corporation RR-A788-3 (2024), gross prices
US brand-name drugs run 4.22x the OECD average and US drugs overall 2.78x, while US generics sit at 67% of the OECD generic price (2022 prices). The multiple lives almost entirely in brands.

Roughly 30% of US adults report not filling a prescription, skipping doses, or cutting pills in half because of cost.Source: KFF Health Tracking Poll on Drug Costs 2023

US Drug Spending

$487 billion#1 US net prescription drug spending in 2024 (after rebates), per IQVIA.
$722 billion#2 US gross prescription drug spending at invoice prices in 2024 before rebates and discounts.
Source: IQVIA Use of Medicines Source not re-confirmed in our October 2026 review.
~9.1%#3 share of total US national health expenditure (NHE) attributable to retail prescription drugs in 2023.
6.5 billion#4 US prescriptions dispensed in 2024 (retail and mail order combined).
Source: IQVIA 2024 Source not re-confirmed in our October 2026 review.
$449.7 billion#5 US retail prescription drug spending in 2023, up 11.4%, per CMS National Health Expenditure data.
Source: CMS NHE 2023
49.9%#6 of people in the US used at least one prescription drug in the past 30 days (2017 to March 2020).
13.5%#7 of people in the US used five or more prescription drugs in the past 30 days (2017 to March 2020).
$1,432#8 mean annual out-of-pocket spending on prescription drugs among Medicare beneficiaries in 2022.
Source: KFF Medicare Part D Key Facts Source not re-confirmed in our October 2026 review.
~30%#9 of US adults report not filling a prescription, skipping doses, or cutting pills due to cost.
$56,000#10 median annual list price of a newly launched US drug in 2023, more than 5x the 2008 median.
Source: ASPE HHS Drug Pricing Issue Briefs Source not re-confirmed in our October 2026 review.

Brand vs Generic Pricing

90%#11 of US prescriptions dispensed are filled with a generic drug.
13.1%#12 share of total US prescription drug spending captured by generics, despite filling 90% of prescriptions.
85%#13 typical cash-price drop from brand to generic within 24 months of first generic competition.
3.4x#14 price premium of single-source generics versus generics with 4 or more ANDA holders.
Source: GAO 2019: Generic Drug Approval and Pricing Source not re-confirmed in our October 2026 review.
$3 trillion+#15 cumulative US savings from generic and biosimilar drug use over the decade to 2023.
39%#16 additional price reduction delivered by the second ANDA holder versus the first.
85%+#17 share of brand-to-generic transitions in the RxGrab 2026 audit that achieved a price drop of 70% or more.
$5.32#18 listed price for 30 tablets of metformin 500mg at Mark Cuban Cost Plus Drugs, including its $5 dispensing fee and before shipping, as of October 2026.
Source: costplusdrugs.com public catalog
$4#19 Walmart cash price for many generics on the Walmart $4 prescription list (30-day supply).
7#20 stalled-generic cases identified in the RxGrab 2026 audit (post-launch price retained 50%+ of brand for 12+ months).

Patent Expiry Trends

$300 billion+#21 estimated global brand drug revenue exposed to patent expiry between 2025 and 2030.
Source: IQVIA Global Use of Medicines 2024 Source not re-confirmed in our October 2026 review.
11 months#22 median time from FDA Orange Book composition-of-matter patent expiry to first generic ANDA approval.
5 of 50#23 brand drugs in the RxGrab 2026 audit had no full generic on the US market: Ozempic, Wegovy, Jardiance, Eliquis (generics FDA-approved December 2019 but not launched) and Xarelto (generic approved only for the 2.5 mg tablet, March 2025).
$55 billion+#24 combined 2024 US sales of the five blockbusters without a full US generic in the RxGrab cohort.
Source: company 10-K disclosures (Novo Nordisk, BMS, Pfizer, Boehringer Ingelheim, Janssen) compiled in RxGrab 2026 audit Source not re-confirmed in our October 2026 review.
2031-2033#25 estimated first generic launch window for semaglutide (Ozempic and Wegovy active ingredient).
Source: ASPE drug pricing analyses and Novo Nordisk patent disclosures
2026#26 Inflation Reduction Act maximum-fair-price effective date for the first 10 negotiated drugs (Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, NovoLog).
132#27 patents AbbVie filed around adalimumab (Humira), the canonical patent thicket case.
Source: I-MAK Humira patent landscape report Source not re-confirmed in our October 2026 review.
~7 years#28 US biosimilar competition delay for Humira after the original composition-of-matter patent expired in 2016.
Source: FTC pay-for-delay analyses and FDA biosimilar approval records
$3 billion+#29 annual revenue settlement-permitted entry deals can preserve for a brand sponsor on a $5B+ blockbuster per year of delay.
15#30 drugs whose Medicare negotiated prices CMS announced on November 25, 2025 in the second IRA cycle, effective January 1, 2027, including Ozempic, Wegovy and Rybelsus.

Generic Approval Rates

~860#31 Abbreviated New Drug Applications (ANDAs) approved by FDA in fiscal year 2023.
Source: FDA CDER Data Dashboard Source not re-confirmed in our October 2026 review.
~30 months#32 median FDA approval time for an Abbreviated New Drug Application (ANDA) in 2023, including review cycles.
Source: FDA ANDA Approvals Tracker Source not re-confirmed in our October 2026 review.
180 days#33 exclusivity granted to the first ANDA filer who challenges a brand's patent and is approved (Hatch-Waxman 180-day exclusivity).
~50#34 First Generics approved by FDA in 2023 (drugs receiving their first ANDA approval).
Source: FDA First Generic Drug Approvals Source not re-confirmed in our October 2026 review.
~12,000#35 approved drug products listed in the FDA Orange Book as of 2024.
9#36 drugs in the RxGrab 2026 audit where the brand sponsor launched a 505(b)(2) line-extension within 36 months of original molecule patent expiry.
~30%#37 share of post-launch generic unit volume captured by authorized generics in their first 12 months.
~20%#38 of FDA-approved brand drugs have an authorized generic listed by the brand sponsor at some point post-launch.
$15 million+#39 typical cost to develop and gain ANDA approval for a single complex generic in 2024.
~62%#40 first-cycle ANDA approval rate after FDA's Drug Competition Action Plan reforms (up from ~9% in 2015).
Source: FDA Drug Competition Action Plan Source not re-confirmed in our October 2026 review.

FDA Orange Book Statistics

1980#41 the year the FDA Orange Book began publication, formalizing therapeutic equivalence ratings (AB, BX, etc.).
AB#42 rating denotes therapeutic equivalence and pharmacy-level substitutability without prescriber authorization (in most states).
~85%#43 of multi-source drug products in the Orange Book are AB-rated, signaling broad substitutability.
BX#44 rating denotes "data are insufficient to determine therapeutic equivalence" and is the most common reason a state pharmacy board blocks substitution.
Source: FDA Orange Book TE codes Source not re-confirmed in our October 2026 review.
~50#45 drug products listed in the FDA Narrow Therapeutic Index list, where dose precision matters more for substitution decisions.
Source: FDA Orange Book Data Files (Drug Approvals and Databases) Source not re-confirmed in our October 2026 review.
3 years#46 of marketing exclusivity granted by FDA for a new indication of an approved drug (data exclusivity).
5 years#47 of new chemical entity exclusivity granted by FDA at first approval, blocking ANDA filings during that window.
7 years#48 of orphan drug exclusivity granted under the Orphan Drug Act for designated rare-disease indications.
6 months#49 of pediatric exclusivity granted by FDA for completing requested pediatric studies, added to existing exclusivity.
~2,000#50 drug products on the FDA Discontinued Drug Products List (Orange Book Discontinued Section) as of 2024.
Source: FDA Orange Book Discontinued Section Source not re-confirmed in our October 2026 review.

Drug Shortages

309#51 active US drug shortages tracked by ASHP at end of 2023, the highest in a decade.
~70%#52 of US drug shortages reported by ASHP affect generic injectables.
72%#53 of the facilities making active pharmaceutical ingredients (APIs) for the US market were outside the United States as of August 2019 (13% in China), per FDA.
2023#54 the year US oncology drug shortages drew national press coverage following carboplatin and cisplatin supply failures.
15.4 months#55 average duration of an active US drug shortage in 2023 per ASHP tracking.
Source: ASHP National Drug Shortages Report Source not re-confirmed in our October 2026 review.
3#56 root causes of drug shortages identified by FDA: too little incentive to make less profitable drugs, a market that does not reward mature quality systems, and logistical and regulatory barriers to recovering from a disruption.

Specialty Drugs

~55%#57 share of US prescription drug spending captured by specialty drugs, despite only ~2% of prescriptions.
$84,000#58 average annual list price of a specialty drug in the US in 2023.
Source: ASPE HHS Specialty Drug Pricing Briefs Source not re-confirmed in our October 2026 review.
~50#59 approved biosimilars in the US as of 2024 across roughly 12 reference biologics.
$36 billion#60 cumulative US savings from biosimilars since their 2015 market entry, through 2023, per the AAM 2024 Savings Report.
2023#61 the year Humira biosimilars launched at scale in the US, ending Humira's 20-year market exclusivity.
~18%#62 typical first-year US list-price discount of a biosimilar versus the originator biologic, well below the 50%+ Europe achieves.
Source: IQVIA Biosimilars Outlook Source not re-confirmed in our October 2026 review.
$3.5 million#63 US list price of one-time gene therapy Hemgenix at launch in 2022, the highest-priced drug in the world at the time.
$26,000-$48,000#64 per-month list price range for new oncology drug launches in 2022-2023.

Prior Authorization

~94%#65 of physicians report that prior authorization delays patient access to necessary care.
39#66 prior authorization requests handled per physician per week on average.
Source: AMA 2023 Prior Authorization Physician Survey Source not re-confirmed in our October 2026 review.
6.4%#67 of Medicare Advantage prior authorization requests were fully or partially denied in 2023; 11.7% of denials were appealed, and 81.7% of appeals overturned the denial.
~$93 billion#68 estimated annual US administrative burden of prior authorization across the healthcare system.
Source: CMS prior authorization burden estimates Source not re-confirmed in our October 2026 review.
2027#69 the year (from January 1) CMS final rule CMS-0057-F requires Medicare Advantage and other impacted payers to run prior authorization APIs; its 72-hour and 7-day decision deadlines began January 1, 2026. Prior authorizations for drugs are excluded.
~80%#70 of US specialty drug prescriptions require prior authorization.
Source: IQVIA Specialty Drug Access Source not re-confirmed in our October 2026 review.

Pharmacy Discounts

$5#71 Mark Cuban Cost Plus Drugs flat dispensing fee added to the cost-plus-15% markup model for each prescription.
67%#72 average price gap between Mark Cuban Cost Plus Drugs and GoodRx coupon-low across 32 audited generics in the RxGrab 2026 study.
~80%#73 typical maximum savings GoodRx markets versus the unsubsidized retail cash price, varying widely by drug.
~32%#74 share of US adults who report using a prescription drug discount card at least once.
Source: KFF Health Tracking Poll Source not re-confirmed in our October 2026 review.
No list#75 Costco Pharmacy does not publish a per-drug cash price list; prices are shown in a logged-in lookup.
$5#76 monthly Amazon Pharmacy RxPass fee for all eligible generics (more than 50), Prime required; not available to Medicaid or CHIP enrollees or for delivery to California and Washington, as of October 2026.
19#77 drugs on the $4 (30-day) / $10 (90-day) tier of Walmart's Prescription Program list effective March 24, 2025; most other listed generics are $9 / $24.
2024#78 the year GoodRx reported $760M+ annual revenue, illustrating the scale of US discount-card economics.

International Comparison

2.78x#79 US drug prices on average versus a basket of 33 OECD comparator countries (gross prices, 2022, RAND 2024).
4.22x#80 US prices versus OECD comparators for brand-name (originator) drugs, 2022 prices (RAND 2024).
67%#81 US unbranded generic prices as a share of OECD comparator prices, 2022 prices (RAND 2024).
~50%#82 typical first-year European biosimilar discount versus originator biologic, more than double the US first-year discount.
2003#83 the year the Medicare Modernization Act prohibited Medicare from directly negotiating drug prices, a constraint partially reversed by the 2022 Inflation Reduction Act for selected drugs.
~$237 billion#84 estimated 10-year US federal savings (2022-2031) from the Inflation Reduction Act drug pricing provisions per CBO.
2026#85 the year RxGrab will refresh this dataset; the brand-to-generic pricing landscape changes meaningfully in 12-month windows around major patent cliffs.
Source: RxGrab 2026 Patent Cliff Audit annual refresh policy